The FDA has granted Priority Review to AiCuris’ new drug application for pritelivir, an oral helicase-primase inhibitor for refractory herpes simplex virus infections, with or without resistance, in immunocompromised patients. The agency set a PDUFA target action date in the fourth quarter of 2026. The filing draws on a pivotal Phase 3 program showing superiority to investigator’s choice therapy, with new data unveiled at ESCMID 2026 indicating higher response rates when treatment extends to 42 days.
The strategic question is whether a first-in-decades antiviral for HSV can reset standards of care for a small but clinically costly population and prove a viable commercial model for precision anti-infectives. For health systems managing growing cohorts of transplant recipients, oncology patients, and individuals on immunosuppressive therapies, pritelivir’s oral, once-daily profile could shift treatment from inpatient, toxicity-laden regimens to outpatient pathways with fewer line-related complications. The extent to which payers recognize those downstream savings will determine adoption speed and set a precedent for similar niche infectious-disease launches.
Clinically, the dataset targets pain points long associated with refractory HSV. In the randomized part of the global, controlled, open-label PRIOH-1 trial, pritelivir met the primary endpoint of superior lesion healing over up to 28 days versus options such as IV foscarnet, IV/topical cidofovir, or topical imiquimod. Extended-treatment findings matter operationally: among patients continuing therapy to 42 days, 82.4% on pritelivir achieved complete lesion healing compared to 42.0% on investigator’s choice, and the median time to undetectable HSV in lesions was 9 days versus 21 days. Treatment effects were consistent across key subgroups, including hematologic malignancies, hematopoietic stem cell and solid organ transplant recipients, and people living with HIV. While renal and electrolyte events were observed, discontinuations were markedly lower with pritelivir than with investigator’s choice (2.0% vs. 20%), reinforcing the potential to de-escalate monitoring intensity relative to foscarnet-based care.
For Commercial leaders, the product profile lends itself to a hospital-initiated, community-completed model. Formulary wins at transplant centers and comprehensive cancer programs, alignment with infectious-disease pharmacists, and pathway updates that define “refractory” triggers will be decisive. Economic models should quantify avoided admissions, reduced central line utilization, and fewer renal consults, while preparing for scrutiny around treatment duration and total drug spend if 42-day courses become common. Coverage strategy will likely straddle inpatient DRG dynamics and outpatient Part D management for Medicare populations, where prior authorization criteria tied to clinical refractoriness rather than genotypic resistance may be pivotal for access at scale.
Medical Affairs will need to lead on diagnostic stewardship and real-world evidence. Clear guidance on when to initiate therapy, how to assess early response to justify extension beyond 28 days, and how to monitor renal and electrolyte parameters in outpatient settings will shape clinician confidence. A prospective registry across transplant and oncology networks could substantiate resource-use reductions and inform subgroup optimization, supporting payer negotiations and guideline inclusion.
The move also sits within a broader recalibration of anti-infectives. Rather than broad-spectrum antibiotics chasing crowded markets, capital is flowing to targeted, high-value antivirals anchored in defined high-risk populations and supported by expedited FDA pathways. AiCuris’ track record in transplant virology and its pending acquisition by Asahi Kasei suggest a strategy built on focused assets that can command premium pricing with clear clinical and operational advantages.
If approval lands on schedule, the next competitive frontier emerges quickly: will helicase-primase inhibition move earlier in the HSV treatment algorithm, and can real-world outcomes convince payers and guideline bodies to back longer-course therapy that delivers durable healing without the inpatient burden of legacy antivirals?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
